BioMérieux has expanded its next-generation sequencing (NGS) infectious disease testing capabilities through the acquisition of Day Zero Diagnostics' assets for approximately $25 million. Day Zero's technology leverages sequencing and machine learning to directly identify pathogens and antimicrobial resistance genes in blood within hours, a significant improvement over traditional multi-day methods. The acquisition includes NGS workflows, bioinformatics, and reagents, further enhancing BioMérieux's automated diagnostic offerings for bloodstream infections and critical conditions. This complements recent collaborative efforts between BioMérieux and Oxford Nanopore to develop sequencing-based infectious disease diagnostics.